Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.
J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.
Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Takeda has been eyeing India’s vaccine market since at least 2015, and the idea has come to fruition in the form of two licensing deals.
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…
European biotech Vaximm has partnered with much bigger drug companies Merck KGaA and Pfizer to test a cancer vaccine/checkpoint inhibitor combo.